AI Article Synopsis

  • New-onset diabetes often improves after pancreaticoduodenectomy (PD), possibly due to increased production of glucagon-like peptide-1 (GLP-1) caused by changes in digestion.
  • The study involved comparing GLP-1 release in 15 patients who had a Whipple procedure versus 15 who had pylorus-preserving surgery, measuring various blood markers after a test meal.
  • Results showed that faster gastric emptying and the type of surgery were linked to higher GLP-1 levels, and patients with Whipple surgery had better blood sugar control compared to those with pylorus preservation.

Article Abstract

Objectives: New-onset diabetes frequently resolves after pancreaticoduodenectomy (PD). Glucagon-like peptide-1 (GLP-1) conceivably is involved as its release is enhanced by rapid gastric emptying and distal bowel exposure to nutrients. We aimed at studying factors associated with GLP-1 release after PD.

Methods: Fifteen PD subjects with distal gastrectomy (Whipple) and 15 with pylorus preservation were evaluated. A test meal containing 1 g paracetamol to measure gastric emptying was ingested. Blood for the measurement of paracetamol, glucose, insulin, and GLP-1 was drawn at baseline and 10, 20, 30, 60, 90, 120, 150, and 180 minutes thereafter. The Matsuda index of insulin sensitivity was calculated.

Results: In univariate analysis, gastric emptying correlated with GLP-1. Glucagon-like peptide-1 responses to the modes of operation did not differ. Multiple regression analysis confirmed gastric emptying and Whipple versus pylorus-preserving pancreaticoduodenectomy as independent predictors of GLP-1 release. The Matsuda index of insulin sensitivity correlated with GLP-1 concentrations and inversely with body mass index. Patients after Whipple procedure revealed lower glycated hemoglobin as compared with pylorus-preserving pancreaticoduodenectomy.

Conclusions: Following PD, the postprandial GLP-1 release seems to be enhanced by rapid gastric emptying and to improve insulin sensitivity. Partial gastrectomy versus pylorus preservation enhanced the release of GLP-1, conceivably because of greater distal bowel exposure to undigested nutrients.

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPA.0000000000001361DOI Listing

Publication Analysis

Top Keywords

gastric emptying
24
glucagon-like peptide-1
12
glp-1 release
12
insulin sensitivity
12
emptying distal
8
distal gastrectomy
8
glp-1
8
glp-1 conceivably
8
release enhanced
8
enhanced rapid
8

Similar Publications

Background/aims: Pediatric patients with suspected gastroparesis often undergo antroduodenal manometry (ADM) and gastric emptying scintigraphy (GES) for diagnostic purposes. However, it is unknown if delayed gastric emptying (DGE) correlates with manometric findings. This study evaluates whether ADM parameters differ between normal and abnormal GES in pediatric patients.

View Article and Find Full Text PDF

Dietary protein reduces energy intake in following meals by signaling directly or indirectly to the brain. We recently observed differences in plasma amino acid kinetics and intra-gastric behavior between micellar casein (MC) and sodium caseinate (SC) in pigs, two factors that impact food intake. Our objective was to clarify whether the supramolecular structure of casein, given as a preload to pigs, impacts on subsequent food intake.

View Article and Find Full Text PDF

Attenuates 5-Fluorouracil-Induced Intestinal Mucositis in Mice.

Pharmaceuticals (Basel)

December 2024

Laboratory of Gastrointestinal Physio-Pharmacology (LEFFAG), Federal University of Ceará, Coronel Nunes de Melo Street, 1315 Rodolfo Teófilo, Fortaleza 60416-030, CE, Brazil.

5-Fluorouracil (5-FU) is an antimetabolite widely prescribed in cancer treatments, but its use in highly proliferative tissues can cause significant problems such as mucositis. is a probiotic commonly used for protection against acute diarrhea, gastrointestinal dysbiosis and inflammatory bowel diseases. We investigated the effect of on 5-FU intestinal mucositis in mice.

View Article and Find Full Text PDF

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are commonly used to treat obesity and diabetes but are linked to a variety of gastrointestinal (GI) adverse events (AEs). Real-world data on GLP-1 RA-related GI AEs and outcomes are limited. This study assessed GI AEs and adverse outcomes using the US FDA Adverse Event Reporting System (FAERS).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!